Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers

Abstract

Melanoma still reaches thousands of new diagnoses per year, and its aggressiveness makes recovery challenging, especially for those with stage III/IV unresectable melanoma. Immunotherapy, emerging as a beacon of hope, stands at the forefront of treatments for advanced melanoma. This review delves into the various immunotherapeutic strategies, prominently featuring cytokine immunotherapy, adoptive cell therapy, immune checkpoint inhibitors, and vaccinations. Among these, immune checkpoint inhibitors, notably anti-programmed cell death-1 (PD-1) and anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies, emerge as the leading strategy. However, a significant subset of melanoma patients remains unresponsive to these inhibitors, underscoring the need for potent biomarkers. Efficient biomarkers have the potential to revolutionize the therapeutic landscape by facilitating the design of personalized treatments for patients with melanoma. This comprehensive review highlights the latest advancements in melanoma immunotherapy and potential biomarkers at the epicenter of recent research endeavors.

Keywords

Melanoma / immunotherapy / resistance mechanism / tumor microenvironment / biomarkers

References

[1] Turner N,Bosenberg M.Genetics of metastasis: melanoma and other cancers.Clin Exp Metastasis2018;35:379-91

[2] Siegel RL,Jemal A.Cancer statistics, 2024.CA Cancer J Clin2024;74:12-49

[3] Han B,Zeng H.Cancer incidence and mortality in China, 2022.JNCC2024;4:47-53

[4] Koczkodaj P,Didkowska J,Mańczuk M.Melanoma mortality trends in 28 European countries: a retrospective analysis for the years 1960-2020.Cancers2023;15:1514 PMCID:PMC10001381

[5] Lopes FCPS,Sebastian K,Jacobs EA.UV exposure and the risk of cutaneous melanoma in skin of color: a systematic review.JAMA Dermatol2021;157:213-9

[6] Dzwierzynski WW.Melanoma risk factors and prevention.Clin Plast Surg2021;48:543-50

[7] Pham JP,da Silva IP,Goldinger SM.Chemotherapy in cutaneous melanoma: is there still a role?.Curr Oncol Rep2023;25:609-21 PMCID:PMC10164011

[8] Carlino MS,Long GV.Immune checkpoint inhibitors in melanoma.Lancet2021;398:1002-14

[9] Mandala M,Ascierto PA.Correction: Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.J Immunother Cancer2021;9:e003188corr1 PMCID:PMC8595983

[10] Dillman RO,Vandermolen LA,Mcclure SE.Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?.Cancer Biother Radio2012;27:337-43

[11] Postow MA,Pavlick AC.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med2015;372:2006-17 PMCID:PMC5744258

[12] Somasundaram R,Herlyn M.Chapter eleven - Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Adv Pharmacol2012;65:335-59 PMCID:PMC3677516

[13] Ng MF,Boyle GM.Heterogeneity in melanoma.Cancers2022;14:3030 PMCID:PMC9221188

[14] Wang DR,Sun YL.Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal Transduct Target Ther2022;7:331 PMCID:PMC9485144

[15] Zhang Y.The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cell Mol Immunol2020;17:807-21 PMCID:PMC7395159

[16] Huang AC.A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.Nat Immunol2022;23:660-70 PMCID:PMC9106900

[17] Leach DR,Allison JP.Enhancement of antitumor immunity by CTLA-4 blockade.Science1996;271:1734-6

[18] Brahmer JR,Wollner I.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J Clin Oncol2010;28:3167-75 PMCID:PMC4834717

[19] Buchbinder EI.CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition.Am J Clin Oncol2016;39:98-106 PMCID:PMC4892769

[20] Patsoukis N,Strauss L.Revisiting the PD-1 pathway.Sci Adv2020;6:eabd2712 PMCID:PMC7500922

[21] Wu Q,Li SC,Yang B.Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.Acta Pharmacol Sin2021;42:1-9 PMCID:PMC7921448

[22] Ivashko IN.Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.Am J Health Syst Pharm2016;73:193-201

[23] Patel SP,Chen Y.Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma.N Engl J Med2023;388:813-23 PMCID:PMC10410527

[24] Amaria RN,Burton EM.Neoadjuvant relatlimab and nivolumab in resectable melanoma.Nature2022;611:155-60 PMCID:PMC9607737

[25] Mallardo D,Vanella V.Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.J Transl Med2022;20:436 PMCID:PMC9523893

[26] Brito ABC,de Lima VCC.Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.Thorac Cancer2021;12:1058-66 PMCID:PMC8017262

[27] Snyder A,Merghoub T.Genetic basis for clinical response to CTLA-4 blockade in melanoma.N Engl J Med2014;371:2189-99 PMCID:PMC4315319

[28] Sarnaik AA.Recent advances using anti-CTLA-4 for the treatment of melanoma.Cancer J2009;15:169-73

[29] Sondak VK,Kudchadkar R,Kirkpatrick P.Ipilimumab.Nat Rev Drug Discov2011;10:411-2

[30] Maio M,Aamdal S.Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.J Clin Oncol2015;33:1191-6 PMCID:PMC5795709

[31] Eggermont AM,Grob JJ.Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.N Engl J Med2016;375:1845-55 PMCID:PMC5648545

[32] Ascierto PA,Mackiewicz A.Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.J Immunother Cancer2020;8:e000391corr1 PMCID:PMC7361996

[33] Seth R,Messersmith H.Systemic therapy for melanoma: ASCO guideline update.J Clin Oncol2023;41:4794-820

[34] Bentebibel SE.Cytokines in the treatment of melanoma.Curr Oncol Rep2021;23:83

[35] Bastholt L,Bjerregaard JK,Hróbjartsson A.High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.Eur J Cancer2019;115:61-7

[36] Davar D,Saul M.High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.J Immunother Cancer2017;5:74 PMCID:PMC5604296

[37] Floros T.Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12.Semin Oncol2015;42:539-48 PMCID:PMC4557618

[38] Xu X,Li C.Interleukins in the treatment of melanoma.Chin Med J2022;135:393-9 PMCID:PMC8869617

[39] Shen J,Zhao Q.Anti-cancer therapy with TNFα and IFNγ: a comprehensive review.Cell Prolif2018;51:e12441 PMCID:PMC6528874

[40] Hansen ML,Krejsgaard T.IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity.Mol Immunol2011;48:2087-93

[41] Kirkwood JM,Ernstoff MS,Borden EC.Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684.J Clin Oncol2023;41:425-35

[42] Shi Q,Zhang W.Interferon-α1b for the treatment of metastatic melanoma: results of a retrospective study.Anticancer Drug2021;32:1105-10

[43] Zhu G,Zhao B.Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study.J Cancer Res Clin Oncol2023;149:6263-9

[44] Davar D,Chauvin J.Phase Ib/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma.J Clin Oncol2018;36:3450-8 PMCID:PMC6286160

[45] Chen L,Li J.CAR-T cell therapy for lung cancer: potential and perspective.Thorac Cancer2022;13:889-99 PMCID:PMC8977151

[46] Xue G,Fang J.Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells.Cancer Cell2021;39:1610-22.e9 PMCID:PMC8678313

[47] Wang S,Chen K.Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.BMC Med2021;19:140 PMCID:PMC8194199

[48] Kumar A,Vilgelm AE.Cell therapy with TILs: training and taming T cells to fight cancer.Front Immunol2021;12:690499 PMCID:PMC8204054

[49] Dafni U,Lluesma SM.Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.Ann Oncol2019;30:1902-13

[50] Leko V.Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors.Cancer Cell2020;38:454-72 PMCID:PMC7737225

[51] Chesney J,Kluger H.Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.J Immunother Cancer2022;10:e005755 PMCID:PMC9748991

[52] Hirai I,Kamijuku H.Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.Cancer Sci2021;112:3163-72 PMCID:PMC8353905

[53] Sarnaik AA,Khushalani NI.Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma.J Clin Oncol2021;39:2656-66 PMCID:PMC8376325

[54] Schoenfeld AJ,Doger de Speville B.Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discovery 2024.

[55] Rosenberg SA,Lafreniere R.A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.Science1986;233:1318-21

[56] Rezaei T,Khalili S.Strategies in DNA vaccine for melanoma cancer.Pigment Cell Melanoma Res2021;34:869-91

[57] Sahin U,Derhovanessian E.An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.Nature2020;585:107-12

[58] Liu S,Zhao X.A DNA nanodevice-based vaccine for cancer immunotherapy.Nat Mater2021;20:421-30

[59] Yazdani Z,Irannejad H,Valadan R.Designing a novel multiepitope peptide vaccine against melanoma using immunoinformatics approach.J Biomol Struct Dyn2022;40:3312-24

[60] Kjeldsen JW,Martinenaite E.A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.Nat Med2021;27:2212-23 PMCID:PMC8904254

[61] Hu Z,Allesøe RL.Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.Nat Med2021;27:515-25 PMCID:PMC8273876

[62] Ott PA,Keskin DB.An immunogenic personal neoantigen vaccine for patients with melanoma.Nature2017;547:217-21 PMCID:PMC5577644

[63] Ott PA,Chmielowski B.A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer.Cell2020;183:347-62.e24

[64] Yin Q,Chang Y.Melanoma stem cell vaccine induces effective tumor immunity against melanoma.Hum Vaccin Immunother2023;19:2158670 PMCID:PMC10114997

[65] Khattak A,Meniawy T.Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.J Clin Oncol2023;41:LBA9503

[66] Topp MS,Stein AS.Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Lancet Oncol2015;16:e158

[67] Park K,Leighl NB.Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study.J Clin Oncol2021;39:3391-402 PMCID:PMC8791812

[68] Nathan P, Hassel JC, Rutkowski P, et al; IMCgp100-202 Investigators. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 2021;385:1196-206.

[69] Hassel JC,Rutkowski P.Three-year overall survival with tebentafusp in metastatic uveal melanoma.N Engl J Med2023;389:2256-66

[70] Tawbi HA, Schadendorf D, Lipson EJ, et al; RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386:24-34. PMCID:PMC9844513

[71] Atkins MB,Chmielowski B.Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134.J Clin Oncol2023;41:186-97 PMCID:PMC9839305

[72] Larkin J,Gonzalez R.Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med2019;381:1535-46

[73] Versluis JM,Rozeman EA.Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.Eur J Cancer2021;148:51-7

[74] Weber JS,Del Vecchio M.Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915).J Clin Oncol2023;41:517-27 PMCID:PMC9870220

[75] Campbell KM,Pfeiffer SM.Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.Cancer Cell2023;41:791-806.e4 PMCID:PMC10187051

[76] Tawbi HA,Algazi A.Combined nivolumab and ipilimumab in melanoma metastatic to the brain.N Engl J Med2018;379:722-30 PMCID:PMC8011001

[77] Anderson NM.The tumor microenvironment.Curr Biol2020;30:R921-5 PMCID:PMC8194051

[78] Zhao H,Yang L.Myeloid-derived itaconate suppresses cytotoxic CD8⁺ T cells and promotes tumour growth.Nat Metab2022;4:1660-73 PMCID:PMC10593361

[79] Singh L,Bhattacharya A.ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells.Mol Cancer Res2021;19:702-16

[80] Jenkins L,Avgustinova A.Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade.Cancer Res2022;82:2904-17 PMCID:PMC9379365

[81] Yao W,Chraa D.Keratinocyte-derived cytokine TSLP promotes growth and metastasis of melanoma by regulating the tumor-associated immune microenvironment.JCI Insight2022;7:e161438 PMCID:PMC9675576

[82] Yang M,Wang Y,Zhang H.Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.Genome Med2022;14:72 PMCID:PMC9264601

[83] Tabolacci C,Mariotti S.Melanoma cell resistance to vemurafenib modifies inter-cellular communication signals.Biomedicines2021;9:79 PMCID:PMC7830125

[84] Pandya P,Stewart-ornstein J.p53 promotes cytokine expression in melanoma to regulate drug resistance and migration.Cells2022;11:405 PMCID:PMC8833998

[85] Lainé A,Hernandez-vargas H.Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation.Nat Commun2021;12:6228 PMCID:PMC8553942

[86] Arkhypov I,Bitsch R.HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.J Immunother Cancer2022;10:e005551 PMCID:PMC9486388

[87] Chen L,Yang Y.CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade.Cancer Discov2018;8:1156-75 PMCID:PMC6205194

[88] Vignard V,Marec N.MicroRNAs in tumor exosomes drive immune escape in melanoma.Cancer Immunol Res2020;8:255-67

[89] Madden MZ.The complex integration of T-cell metabolism and immunotherapy.Cancer Discov2021;11:1636-43 PMCID:PMC8295173

[90] Elia I,Johnson S.Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8⁺ T cells.Cell Metab2022;34:1137-50.e6 PMCID:PMC9357162

[91] Chen G,Zhang W.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.Nature2018;560:382-6 PMCID:PMC6095740

[92] Huang L,Fang J.Targeting STAT3 abrogates Tim-3 upregulation of adaptive resistance to PD-1 blockade on regulatory T cells of melanoma.Front Immunol2021;12:654749 PMCID:PMC8082190

[93] Kreidieh FY.The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.Ther Adv Med Oncol2023;15:17588359231186027 PMCID:PMC10357068

[94] Adashek JJ,Nishizaki D.LAG-3 transcriptomic expression patterns across malignancies: implications for precision immunotherapeutics.Cancer Med2023;12:13155-66 PMCID:PMC10315766

[95] Solinas C,Bron D,Sangiolo D.Significance of TIM3 expression in cancer: from biology to the clinic.Semin Oncol2019;46:372-9

[96] Frankiw L,Peters C.Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.J Immunother Cancer2023;11:e006930 PMCID:PMC10173990

[97] Shalabi H,Wang HW.Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.Haematologica2018;103:e215-8 PMCID:PMC5927974

[98] Baba T,Kuroda K.Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.Int J Clin Oncol2013;18:997-1004

[99] Dhatchinamoorthy K,Rock KL.Cancer immune evasion through loss of MHC class I antigen presentation.Front Immunol2021;12:636568 PMCID:PMC7986854

[100] Wculek SK,Mujal AM,Krummel MF.Dendritic cells in cancer immunology and immunotherapy.Nat Rev Immunol2020;20:7-24

[101] Hilligan KL.Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses.Cell Mol Immunol2020;17:587-99 PMCID:PMC7264306

[102] Hargadon KM,Brandt JP,Ararso YT.Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.Immunol Cell Biol2016;94:24-38

[103] Dolina JS,Thomas GD.CD8⁺ T cell exhaustion in cancer.Front Immunol2021;12:715234 PMCID:PMC8330547

[104] Peng DH,Diao L.Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8⁺ T cell exhaustion.Nat Commun2020;11:4520 PMCID:PMC7481212

[105] Plaschka M,Grimont M.ZEB1 transcription factor promotes immune escape in melanoma.J Immunother Cancer2022;10:e003484 PMCID:PMC8921918

[106] Galbo PM,Zheng D.Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance.Clin Cancer Res2021;27:2636-47 PMCID:PMC8102353

[107] Tian J,Chao SX.Combined PD-1, BRAF and MEK inhibition in BRAF^V600E colorectal cancer: a phase 2 trial.Nat Med2023;29:458-66 PMCID:PMC9941044

[108] Cabrita R,Sanna A.The role of PTEN loss in immune escape, melanoma prognosis and therapy response.Cancers2020;12:742 PMCID:PMC7140048

[109] Yu J,Song J.Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma.Front Pharmacol2022;13:928226 PMCID:PMC9459091

[110] Gao J,Zhao H.Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy.Cell2016;167:397-404.e9 PMCID:PMC5088716

[111] Yen I,Lee J.ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.Nature2021;594:418-23

[112] Kim TK,Herbst RS.Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.Nat Rev Drug Discov2022;21:529-40

[113] Tímár J.Molecular pathology of skin melanoma: epidemiology, differential diagnostics, prognosis and therapy prediction.Int J Mol Sci2022;23:5384 PMCID:PMC9140388

[114] Teixido C,Martinez-Vila C,Alos L.Molecular markers and targets in melanoma.Cells2021;10:2320 PMCID:PMC8469294

[115] Nebhan CA.Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.Expert Rev Anticancer Ther2020;20:137-45 PMCID:PMC7040956

[116] Paver EC,Colebatch AJ.Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.Pathology2021;53:141-56

[117] Herbst RS,Kowanetz M.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014;515:563-7 PMCID:PMC4836193

[118] Powles T,Fine GD.MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.Nature2014;515:558-62

[119] Yang Z,Liu S.Enhancing PD-L1 degradation by ITCH during MAPK inhibitor therapy suppresses acquired resistance.Cancer Discov2022;12:1942-59 PMCID:PMC9357203

[120] Doroshow DB,Beasley MB.PD-L1 as a biomarker of response to immune-checkpoint inhibitors.Nat Rev Clin Oncol2021;18:345-62

[121] Lawlor RT,Mafficini A.Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions.Cancers2021;13:3119 PMCID:PMC8269341

[122] Hellmann MD,Bernabe Caro R.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.N Engl J Med2019;381:2020-31

[123] Chae YK,Raparia K.Association of tumor mutational burden with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.Clin Lung Cancer2019;20:88-96.e6

[124] Dedeurwaerdere F,Van Dorpe J.Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer.Sci Rep2021;11:12880 PMCID:PMC8213758

[125] Shimozaki K,Tanishima S.Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors.Sci Rep2021;11:20003 PMCID:PMC8501090

[126] Le DT,Smith KN.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science2017;357:409-13 PMCID:PMC5576142

[127] Schumacher TN.Tertiary lymphoid structures in cancer.Science2022;375:eabf9419

[128] Fridman WH,Petitprez F,Italiano A.B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.Nat Rev Clin Oncol2022;19:441-57

[129] Cabrita R,Sanna A.Tertiary lymphoid structures improve immunotherapy and survival in melanoma.Nature2020;577:561-5

[130] Blanchard L.High endothelial venules (HEVs) in immunity, inflammation and cancer.Angiogenesis2021;24:719-53 PMCID:PMC8487881

[131] Asrir A,Coudert J.Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.Cancer Cell2022;40:318-34.e9

[132] Xiong D,You M.A gene expression signature of TREM2^hi macrophages and γδ T cells predicts immunotherapy response.Nat Commun2020;11:5084 PMCID:PMC7545100

[133] Liu Y,Yang Y,Sun J.The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.Br J Cancer2023;129:1041-9 PMCID:PMC10539364

[134] Denkert C,Darb-Esfahani S.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.Lancet Oncol2018;19:40-50

[135] Loi S,Adams S.Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers.J Clin Oncol2019;37:559-69 PMCID:PMC7010425

[136] Huang R,Lu Y,Liao L.A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment.Aging2020;12:6966-80 PMCID:PMC7202520

[137] Chilakapati SR,Zsiros E.Microbiome and cancer immunotherapy.Curr Opin Biotechnol2020;65:114-7

[138] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103 PMCID:PMC5827966

[139] Gunjur A,Rozday T.A gut microbial signature for combination immune checkpoint blockade across cancer types.Nat Med2024;30:797-809 PMCID:PMC10957475

[140] Hoy AJ,Butler LM.Tumour fatty acid metabolism in the context of therapy resistance and obesity.Nat Rev Cancer2021;21:753-66

[141] Lang X,Cui H.Prognosis analysis and validation of fatty acid metabolism-related lncRNAs and tumor immune microenvironment in cervical cancer.J Immunol Res2022;2022:4954457 PMCID:PMC9356243

[142] Xu Y,Jiang W.Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.Front Immunol2022;13:967277 PMCID:PMC9716430

[143] Zhao R,Buhl S.HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.Proc Natl Acad Sci U S A2013;110:9879-84 PMCID:PMC3683785

[144] Xu G,Ling X.HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer.Cancer Cell Int2021;21:252 PMCID:PMC8106145

[145] Huang F,Cheng X.HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.Front Immunol2022;13:902167 PMCID:PMC9395140

[146] Gassenmaier M,Forschner A.Serum S100B and LDH at baseline and during therapy predict the outcome of metastatic melanoma patients treated with BRAF inhibitors.Target Oncol2021;16:197-205 PMCID:PMC7935737

[147] Long GV,Nathan P.Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.Lancet Oncol2016;17:1743-54

[148] Knispel S,Menzies AM.Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.Eur J Cancer2021;148:61-75

[149] Capone M,Mallardo D.Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.J Immunother Cancer2018;6:74 PMCID:PMC6048712

[150] Mallardo D,White A.CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.J Transl Med2023;21:610 PMCID:PMC10492378

[151] Lauwyck J,Santens A.C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting.Melanoma Res2021;31:371-7

[152] Yoshida T,Giuroiu I.C reactive protein impairs adaptive immunity in immune cells of patients with melanoma.J Immunother Cancer2020;8:e000234 PMCID:PMC7204799

[153] Valpione S,Tweedy J.Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.Nat Cancer2020;1:210-21 PMCID:PMC7046489

[154] Valpione S,Galvani E.The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival.Nat Commun2021;12:4098 PMCID:PMC8253860

[155] Kao CY.Extracellular vesicles: exosomes, microparticles, their parts, and their targets to enable their biomanufacturing and clinical applications.Curr Opin Biotechnol2019;60:89-98

[156] Buzas EI.The roles of extracellular vesicles in the immune system.Nat Rev Immunol2023;23:236-50 PMCID:PMC9361922

[157] Dou X,Chen Z,Li M.Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.Clin Exp Immunol2022;207:307-17 PMCID:PMC9113186

[158] Serratì S,Di Fonte R.Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.Mol Cancer2022;21:20 PMCID:PMC8764806

[159] Splendiani E,Covre A,Di Giacomo AM.Immunotherapy in melanoma: can we predict response to treatment with circulating biomarkers?.Pharmacol Ther2024;256:108613

[160] Wu F,He Y.Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer.Nat Commun2021;12:2540 PMCID:PMC8100173

[161] Tarighati E,Mahani H.A review of prognostic and predictive biomarkers in breast cancer.Clin Exp Med2023;23:1-16

[162] Sechidis K,Metcalfe PD,Weatherall J.Distinguishing prognostic and predictive biomarkers: an information theoretic approach.Bioinformatics2018;34:4139 PMCID:PMC6247935

[163] Montaner J,Simats A.Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke.Nat Rev Neurol2020;16:247-64

[164] Miñoza JMA,Zamora PRF.Biomarker discovery for meta-classification of melanoma metastatic progression using transfer learning.Genes2022;13:2303 PMCID:PMC9777873

[165] Chan L,Fleming F.Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.Diabetologia2021;64:1504-15 PMCID:PMC8187208

[166] Chang CH,Lane HY.Machine learning and novel biomarkers for the diagnosis of Alzheimer’s disease.Int J Mol Sci2021;22:2761 PMCID:PMC7963160

[167] Kao C,Wu Y.Predictive value of combining biomarkers for clinical outcomes in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.Clin Lung Cancer2021;22:500-9